Mélanie Serrero

Mélanie Serrero

Auto-generated profile, based on publicly available information

Mélanie Serrero

Department of Gastroenterology, Hôpital Nord, AP-HM, Marseille, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MSMélanie Serrero
Mélanie Serrero
FGFanny Grimaud
Fanny Grimaud
CPCécile Philandrianos
Cécile Philandrianos
CVCarine Visée
Carine Visée
FSFlorence Sabatier
Florence Sabatier
JGJean-Charles Grimaud
Jean-Charles Grimaud

10 January 2018 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
CPCécile Philandrianos
Cécile Philandrianos
MSMélanie Serrero
Mélanie Serrero
FGFanny Grimaud
Fanny Grimaud
JMJeremy Magalon
Jeremy Magalon
CVCarine Visée
Carine Visée
FSFlorence Sabatier
Florence Sabatier
Mesenchymal stem cell therapy is a promising treatment for perianal Crohn’s fistulas refractory to conventional therapy, which are an extremely morbid complication and a true therapeutic challenge. Autologous adipose-derived stromal vascular fraction (ADSVF) is an easily accessible source of cells with angiogenic, anti-inflammatory, immunomodulatory, and regenerative properties. Here, we describe a case involving a patient with severe perianal Crohn’s fistulas refractory to the best medical and surgical practices who received local treatment with ADSVF and microfat. This patient was first examined under anesthesia with drainage via seton placement; 1 week later, on a single day, he underwent adipose tissue extraction, ADSVF and microfat preparation, and the local injection of 14 ml of microfat and approximately 20 million viable ADSVF cells into the soft tissue around the fistulas. No serious adverse events were observed. At the first endpoint at 12 weeks, the fistula had clinically healed with complete re-epithelialization of all external openings; no fistula tract was detected on magnetic resonance imaging, confirming this finding. This good clinical outcome was sustained at 48 weeks and was associated with a reduction in the severity of perianal disease and an improvement in quality of life. The current case highlights the therapeutic potential of a new cellular treatment for Crohn’s patients with refractory perianal fistulas based on the innovative hypothesis that the combined action of ADSVF in association with the trophic characteristics of a microfat graft could be beneficial for this condition. Trial registration: EudraCT number 201325, NCT02520843 . Registered on 5 August 2015

1 August 2023 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
LGLucas Guillo
Lucas Guillo
GSGuillaume Savoye
Guillaume Savoye
AAAMIOT Aurelien
AMIOT Aurelien
CGCyrielle Gilletta
Cyrielle Gilletta
MNMaria Nachury
Maria Nachury
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet
INTRODUCTION: Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors of EIMs. The aim of this study was to prospectively investigate the epidemiology, risk factors of EIM occurrence, and EIM remission in a large IBD cohort. METHODS: We conducted a cross-sectional study in 30 French referral centers. Between May 2021 and June 2021, all consecutive patients attending to hospital appointment were systematically invited to fill out a questionnaire. RESULTS: A total of 1,971 consecutive patients with IBD were analyzed. There were 1,056 women (53.8%), and the median age of patients was 41 years (31–54). The median disease duration was 11 years (1–18). Overall, 544 (27.6%) had at least 1 EIM. In 20.2% of cases, patients had multiple EIMs. The most frequent EIMs were rheumatological (19%) and dermatological (10%) manifestations. Immunosuppressant treatment (odds ratio [OR] = 2.56; P < 0.001) was a risk factor of EIM, while the Montreal A3 classification (OR = 0.61, P = 0.023) and male gender (OR = 0.61, P < 0.001) were associated with a lower risk of EIM occurrence. IBD current clinical remission (OR = 2.42; P < 0.001) and smoking cessation (OR = 2.98; P < 0.001) were associated factors of EIM remission. Conversely, age at IBD diagnosis (OR = 0.98; P < 0.018) was associated with a lower risk of EIM remission. DISCUSSION: One quarter of patients had at least 1 EIM. Beyond factors associated with the presence of EIMs, patients with IBD current clinical remission and smoking cessation are more likely to achieve EIM remission, while increasing age at IBD diagnosis is associated with decreased chance of remission.

1 April 2021 in Digestive and Liver Disease
Verified
Journal Article
Closed access
MNMaria Nachury
Maria Nachury
YBYoram Bouhnik
Yoram Bouhnik
MSMelanie Serrero
Melanie Serrero
JFJerome Filippi
Jerome Filippi
Xavier RoblinXavier Roblin
Xavier Roblin
LPLaurence Picon
Laurence Picon

1 December 2019 in Gastroenterology
Verified
Journal Article
Closed access
FGFanny Grimaud
Fanny Grimaud
MSMélanie Serrero
Mélanie Serrero
JMJérémy Magalon
Jérémy Magalon

3 February 2026 in Digestive and Liver Disease
Verified
Journal Article
Open access
MGMaud Gendard
Maud Gendard
PSPhilippe SEKSIK
Philippe SEKSIK
CSCarmen Stefanescu
Carmen Stefanescu
AMAntoine Meyer
Antoine Meyer
MNMaria Nachury
Maria Nachury
AAAMIOT Aurelien
AMIOT Aurelien
The impact of Physical activity (PA) on the activity of inflammatory bowel disease (IBD) remains unclear. A descriptive cross-sectional study included consecutive patients with Crohn's disease (CD), ulcerative colitis (UC). PA was assessed using the short International Physical Activity Questionnaire. PA was classified as low, medium or high PA. PA was also assessed according to WHO recommendations. IBD activity was evaluated using PRO-2, while IBD-related disability was assessed with the IBD-disk questionnaire. Among a total of 2514 patients (1715 CD), only 28.8% met the WHO recommendations on PA (49.8% had low PA, 35.2% had medium PA, and 15.0% had high PA). Medium and high PA levels were associated with a higher rate of patient-reported clinical remission in patients with CD (OR 1.30 [1.08-1.57] for medium PA, and 1.33 [1.03-1.72] for high PA vs. low PA; p-trend=0.02) but not in those with UC. Higher PA levels were associated with less IBD-related disability in both CD, and UC. In a large cohort of IBD patients, moderate and high PA was associated with higher rates of clinical remission in patients with CD and lower IBD-related disability in both CD and UC patients.